PT  - JOURNAL ARTICLE
AU  - Breton, Theodore R.
TI  - A Method to Identify the Missing COVID-19 Cases in the U.S. and Results for mid-April 2020
AID  - 10.1101/2020.04.28.20083782
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.28.20083782
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.28.20083782.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.28.20083782.full
AB  - I use the COVID-19 death rate in South Korea and a method relating the ratio of death rates in a U.S. state to its share of cumulative positive tests to estimate the total cases of COVID-19 in the U.S. and to estimate the extent of infection and the unidentified share of the infected population in each of the lower-48 states and in New York City in mid-April, 2020. I identify a logarithmic relationship between the cumulative death rate in a state and its cumulative positive share of tests. Using this relationship, I find that 4.3-5.4 million people, 1.4-1.7% of the U.S. population, were infected, with rates of infection that ranged from 0.1% in more rural states to 8-10% in New York state and 11-13% in New York City. Only 16-20% of these infected individuals were identified later through testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received to support this research.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available in an SSRN paper with Abstract ID 3583941, as soon as this paper is approved for posting.